In Depth 18 Sep 2024 Two targets, one solution: The rise of bispecific antibodies …to manufacture only one molecule and patients may need only one antibody treatment. This is beneficial because it lessens the patient burden and also overcomes the potential issues surrounding the… September 18, 2024 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2019 HiFiBiO’s €60M Series C to Fund Cancer and Autoimmune Disease Antibody Drugs …also fuel the expansion of HiFiBiO’s antibody production technology, which is based on screening hundreds of single immune cells at a time for the most effective antibody drug candidate. HiFiBiO… August 29, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Oxford BioTherapeutics enters into antibody agreement with Genmab …conjugate (ADC) based therapies designed to fulfill major unmet patient needs in cancer therapeutics. These include bispecific, chimeric antigen receptor T-cell (CAR-T), Antibody Drug Conjugate (ADC) and Antibody Dependent Cell-mediated… October 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 United BioPharma gets FDA approval for phase 2 HIV drug trial …multi-drug resistance (MDR). The study protocol is entitled: “A Single arm Open Label Phase 2 trial of anti-CD4 Antibody UB-421 in Combination with Optimized Background Antiretroviral Therapy in Patients with… August 31, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 Potential targets against natural killer/T-cell lymphoma found …greatly needed. We can use different strategies to target these. Proteolysis-targeting chimera (PROTAC) targeting TOX2 to degrade TOX2 protein may be a viable NKTL therapy option. A humanized antibody, PRL3-zumab,… May 30, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 8 Feb 2017 The First Stroke Drug in Decades? French Biotech gets closer to the Clinic …Medicine & Healthcare products Regulatory Agency (MHRA) received in January. Acticor’s candidate, ACT017, is a humanized antibody fragment (Fab) that inhibits the activity of platelet glycoprotein VI (GPVI). This strategy… February 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 Lipum starts chronic inflammatory disease drug study …have received a dose, with two volunteers receiving placebo. Lipum’s drug candidate SOL-116 is a fully humanized antibody that is intended to address a major unmet medical need in the… November 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 27 Apr 2017 Spain: An Emerging Star in the European Biotech Community …has been a great opportunity for Versant Ventures and Canadian Northern Biologicals. Mosaic and Northern merged late last year to propel Mosaic’s humanized antibody into clinical trials for oncology this… April 27, 2017 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2017 What to Do When the Microorganisms Get to You …thrombus formation without disrupting natural hemostasis. ACT017 is a humanized antibody fragment which inhibits the platelet glycoprotein VI that plays a role in thrombus growth. Phase I clinical trials are… September 6, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Best in Biotech 29 Feb 2024 6 biotech companies making a difference in pediatric care …announced the signing of an exclusive license agreement with St. Jude Children’s Research Hospital for its lead candidate Hu14.18, a humanized antibody in development by St. Jude for the treatment… February 29, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 23 May 2025 Finland: Pushing biotech forward in the land of a thousand lakes …results Faron Pharmaceuticals, based in Turku, Finland, is a clinical-stage biopharmaceutical company developing immunotherapies for cancer and other diseases. The company’s lead product, bexmarilimab, is a humanized antibody that targets… May 23, 2025 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2017 Tiziana‘s Antibody Formulation Enters Phase IIa Trial for Liver Disease Treatment Tiziana makes moves towards a €37B market with an oral monoclonal antibody (mAb) formulation to treat non-alcoholic steatohepatitis (NASH) . Tiziana, which has previously developed compounds targeting the second most… September 6, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email